ArticleSurgical endoscopy2026
Impact of preoperative cannabis use on outcomes following surgical intervention for gastroparesis.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCannabis use has been associated with delayed gastric emptying and may worsen symptoms in patients with gastroparesis. However, its impact on postoperative outcomes after surgical treatment remains unclear. This study aimed to evaluate postoperative outcomes among patients with and without preoperative cannabis use undergoing surgical intervention for gastroparesis.
methodsA retrospective cohort study was conducted using the TriNetX federated electronic medical record database. Adults with gastroparesis who underwent pyloric drainage surgery or gastric stimulator placement were stratified by cannabis use (ICD-10 F12) prior to surgery. Outcomes were assessed over the first 90 days and up to 5 years postoperatively. Statistical comparisons included risk analysis, Kaplan-Meier survival, and number of instances.
resultsThe study cohort consisted of 1,572 patients, including 108 (6.9%) with documented preoperative cannabis use. Patients with cannabis use were younger (39.8 vs 44.6 years, p = 0.002) and had higher rates of diabetes (56.5% vs 45.1%, p = 0.033), GERD (77.7% vs 65.1%, p = 0.014), nausea/vomiting (85.2% vs 59.4%, p < 0.001), and abdominal pain (73.1% vs 50.2%, p < 0.001). Within 90 days of surgery, cannabis users experienced higher rates of reintervention (9.3% vs 1.2%, p < 0.001) and inpatient admissions (32.4% vs 23.7%, p = 0.042), but fewer clinic visits (37.0% vs 54.5%, p < 0.001). By 5 years, cannabis users demonstrated persistently greater inpatient utilization with higher hospital admission rates (59.3% vs 41.0%, p < 0.0001) and shorter time to first admission (log-rank p < 0.001). Outpatient engagement was significantly lower, with fewer patients attending follow-up (54.6% vs 76.2%, p < 0.001), fewer total clinic encounters (8.1 vs 12.3, p = 0.045), and longer time to first clinic visit (log-rank p < 0.001). Rates of gastrectomy (0.0% vs 0.7%, p = 0.541) and late reintervention (12.0% vs 11.3%, p = 0.808) were similar between groups. DISCUSSION: Preoperative cannabis use is associated with a greater symptom burden, increased early reintervention, reduced outpatient engagement, and greater long-term healthcare utilization after surgical intervention for gastroparesis. These patients may represent a more symptomatic population and may benefit from closer follow-up to reduce readmissions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.